{"id":447712,"date":"2021-03-01T18:03:28","date_gmt":"2021-03-01T23:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=447712"},"modified":"2021-03-01T18:03:28","modified_gmt":"2021-03-01T23:03:28","slug":"cytosorbents-to-report-fiscal-2020-operating-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/","title":{"rendered":"CytoSorbents to Report Fiscal 2020 Operating and Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MONMOUTH JUNCTION, N.J.<\/span>, March 1, 2021<\/span> \/PRNewswire\/ —\u00a0CytoSorbents Corporation<\/a>\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,\u00a0will report fiscal 2020 financial results on Tuesday, March 9, 2021<\/span> at 4:45PM EST<\/span>.\u00a0 <\/p>\n

\n

\n
\n \"CytoSorbents
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n

CytoSorbents Corporation to Report Q4 2020 and Fiscal 2020 Operating and Financial Results on Tuesday, March 9, 2021<\/span><\/div>\n

CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2020 and fiscal year ending December 31, 2020<\/span> followed by a question and answer session.<\/p>\n

Conference Call Details:
Date: Tuesday, March 9, 2021<\/span>
Time: 4:45 PM<\/span> Eastern
Participant Dial-In: \u00a0201-389-0879
Conference ID:\u00a0 13716351
Live Presentation Webcast: \u00a0http:\/\/public.viavid.com\/index.php?id=143499<\/a><\/p>\n

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.\u00a0 There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link:\u00a0http:\/\/public.viavid.com\/index.php?id=143499<\/a><\/p>\n

\n http:\/\/public.viavid.com\/index.php?id=108451<\/a>
\n http:\/\/public.viavid.com\/index.php?id=105816<\/a>An archived recording and written transcript of the conference call will be available under the Investor Relations section of the Company’s website at http:\/\/cytosorbents.com\/investor-relations\/financial-results\/<\/a><\/p>\n

\n About CytoSorbents Corporation (NASDAQ: CTSO<\/a>)<\/b>\n <\/p>\n

\n CytoSorbents Corporation<\/a>\u00a0is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb\u00ae<\/a>\u00a0is approved in the European Union with distribution in 67 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.\u00a0 CytoSorb\u00ae<\/a>\u00a0is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb\u00ae has been used in more than 121,000 human treatments to date.\u00a0 CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and both ticagrelor<\/a>\u00a0and rivaroxaban<\/a>\u00a0during cardiothoracic surgery.\u00a0 CytoSorb has also received FDA Emergency Use Authorization<\/a>\u00a0in the United States<\/span> for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.\u00a0 CytoSorb has also been granted FDA Breakthrough Designation<\/a>\u00a0for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.<\/p>\n

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million<\/span> from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF\/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY\u2122, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ\u2122, K+<\/sup>ontrol\u2122, DrugSorb\u2122, ContrastSorb, and others.\u00a0 \u00a0\u00a0For more information, please visit the Company’s websites at www.cytosorbents.com<\/a>\u00a0and www.cytosorb.com<\/a>\u00a0or follow us on Facebook<\/a>\u00a0and Twitter<\/a>.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on\u00a0March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n

\n
\n Please Click to Follow Us on Facebook<\/a> and Twitter<\/a><\/u>
\n <\/b>\n <\/p>\n

\u00a0<\/p>\n

\n\n\n\n
\n

\n
\n Cytosorbents Contact:<\/b>
\n
Amy Vogel<\/span>\n <\/p>\n

\n 732-398-5394<\/span>\n <\/p>\n

\n
\n
\n avogel@cytosorbents.com<\/a>
\n <\/u>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\u00a0<\/p>\n

\n
\n Public Relations Contact:<\/b>
\n <\/span>\n <\/p>\n

\n Eric Kim<\/span>\n <\/p>\n

\n Rubenstein Public Relations<\/span>\n <\/p>\n

\n 212-805-3052<\/span>\n <\/p>\n

\n
\n ekim@rubensteinpr.com<\/a>
\n <\/span>\n <\/p>\n

\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results-301237907.html<\/a><\/p>\n

SOURCE CytoSorbents Corporation<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MONMOUTH JUNCTION, N.J., March 1, 2021 \/PRNewswire\/ —\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,\u00a0will report fiscal 2020 financial results on Tuesday, March 9, 2021 at 4:45PM EST.\u00a0 CytoSorbents Corporation to Report Q4 2020 and Fiscal 2020 Operating and Financial Results on Tuesday, March 9, 2021 CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2020 and fiscal year ending December 31, 2020 followed by a question and answer session. Conference Call Details:Date: Tuesday, March 9, 2021Time: 4:45 PM EasternParticipant Dial-In: \u00a0201-389-0879Conference ID:\u00a0 13716351Live Presentation Webcast: \u00a0http:\/\/public.viavid.com\/index.php?id=143499 It … <\/p>\n

Continue reading “CytoSorbents to Report Fiscal 2020 Operating and Financial Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-447712","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCytoSorbents to Report Fiscal 2020 Operating and Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents to Report Fiscal 2020 Operating and Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MONMOUTH JUNCTION, N.J., March 1, 2021 \/PRNewswire\/ —\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,\u00a0will report fiscal 2020 financial results on Tuesday, March 9, 2021 at 4:45PM EST.\u00a0 CytoSorbents Corporation to Report Q4 2020 and Fiscal 2020 Operating and Financial Results on Tuesday, March 9, 2021 CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2020 and fiscal year ending December 31, 2020 followed by a question and answer session. Conference Call Details:Date: Tuesday, March 9, 2021Time: 4:45 PM EasternParticipant Dial-In: \u00a0201-389-0879Conference ID:\u00a0 13716351Live Presentation Webcast: \u00a0http:\/\/public.viavid.com\/index.php?id=143499 It … Continue reading "CytoSorbents to Report Fiscal 2020 Operating and Financial Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-01T23:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/320713\/cytosorbents_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents to Report Fiscal 2020 Operating and Financial Results\",\"datePublished\":\"2021-03-01T23:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/\"},\"wordCount\":840,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/320713\\\/cytosorbents_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/\",\"name\":\"CytoSorbents to Report Fiscal 2020 Operating and Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/320713\\\/cytosorbents_logo.jpg\",\"datePublished\":\"2021-03-01T23:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/320713\\\/cytosorbents_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/320713\\\/cytosorbents_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents to Report Fiscal 2020 Operating and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents to Report Fiscal 2020 Operating and Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents to Report Fiscal 2020 Operating and Financial Results - Market Newsdesk","og_description":"PR Newswire MONMOUTH JUNCTION, N.J., March 1, 2021 \/PRNewswire\/ —\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,\u00a0will report fiscal 2020 financial results on Tuesday, March 9, 2021 at 4:45PM EST.\u00a0 CytoSorbents Corporation to Report Q4 2020 and Fiscal 2020 Operating and Financial Results on Tuesday, March 9, 2021 CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2020 and fiscal year ending December 31, 2020 followed by a question and answer session. Conference Call Details:Date: Tuesday, March 9, 2021Time: 4:45 PM EasternParticipant Dial-In: \u00a0201-389-0879Conference ID:\u00a0 13716351Live Presentation Webcast: \u00a0http:\/\/public.viavid.com\/index.php?id=143499 It … Continue reading \"CytoSorbents to Report Fiscal 2020 Operating and Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-01T23:03:28+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/320713\/cytosorbents_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents to Report Fiscal 2020 Operating and Financial Results","datePublished":"2021-03-01T23:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/"},"wordCount":840,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/320713\/cytosorbents_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/","name":"CytoSorbents to Report Fiscal 2020 Operating and Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/320713\/cytosorbents_logo.jpg","datePublished":"2021-03-01T23:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/320713\/cytosorbents_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/320713\/cytosorbents_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-fiscal-2020-operating-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents to Report Fiscal 2020 Operating and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=447712"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447712\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=447712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=447712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=447712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}